Monoclonal Antibodies: A Transformative Force in Biopharmaceuticals, Driving Growth in Antibody Discovery Services and Platforms

2023-10-19
PRNewswire
并购免疫疗法
DUBLIN, Oct. 19, 2023 /PRNewswire/ -- The "Antibody Discovery Market: Focus on Services and Platforms - Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2023-2035" report has been added to
ResearchAndMarkets.com's offering.
The global antibody discovery services and platforms market is poised for significant growth, with a projected value of over $1.6 billion in 2023 and a forecasted Compound Annual Growth Rate (CAGR) of 12.0% during the coming years. The market is driven by pharmaceutical companies' increasing reliance on outsourcing antibody discovery processes and the growing demand for targeted therapies.
Streamlining Drug Development with Outsourcing
The traditional drug development process is lengthy, spanning 10-15 years and involving investments of over $2 billion. Despite these efforts and investments, more than 90% of drug candidates fail in clinical trials. To streamline drug development, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical companies are increasingly outsourcing their discovery-stage operations to specialized contract research organizations (CROs). Outsourcing allows companies to optimize resource utilization, save costs, and tap into a global network of scientific talent, ultimately enhancing the efficiency and success rate of bringing novel antibody-based therapeutics to market.
Evolution of Monoclonal Antibodies
Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3, in 1986, monoclonal antibodies have become a versatile class of biopharmaceuticals. These antibodies have seen significant advancements in engineering, format diversification, and discovery methods. Over 160 monoclonal antibodies have been approved worldwide for the treatment of diseases such as cancer, chronic inflammatory diseases, infectious diseases, and cardiovascular diseases. Recent approvals include ELREXFIOT, TALVEYT, Rystiggo, COLUMVI, and EPKINLYT. Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market.
Market Drivers: Biotech Advancements and Increasing Demand
Key drivers of the global antibody discovery services and platforms market include recent advancements in biotechnology, a growing demand for targeted therapies, rising prevalence of chronic diseases, increased R&D expenditure in the pharmaceutical industry, and a growing trend of outsourcing antibody discovery. Collaborations between academic institutions and antibody discovery companies further contribute to market growth.
Market Size and Segments
The global market size for antibody discovery services and platforms is projected to grow at an annualized CAGR of 11.0% during the forecast period. The hit generation segment holds the largest market share, driven by its significance in R&D expenditure. In terms of the antibody discovery method, the hybridoma method is dominant, thanks to its capability to create immortalized cell lines for continuous antibody manufacturing.
Regional Analysis: North America Leads
North America currently captures nearly 40% of the market, driven by a rising interest in advanced antibody discovery platforms and increased outsourcing in the pharmaceutical industry. North America is anticipated to grow at a CAGR of 12% during the forecast period.
Key Players and Recent Developments
Key players in the antibody discovery services and platforms market include Ablexis, Antibody Solutions, ChemPartner, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, and more. Recent developments in the field include the launch of transgenic mouse-based antibody discovery platforms and initiatives to support the discovery of bispecific antibody formats.
Recent Developments:
In June 2023, AbTherx announced the launch of its transgenic mouse-based antibody discovery platform, AtlasT Mice.
In June 2023, Sanyou Biopharmaceuticals, a China-based company, launched its Sanyou Super Trillion Common Light Chain Antibody Discovery Platform, which supports the discovery of bispecific antibody formats.
In January 2023, IASO Biotherapeutics raised USD 75 million in a venture series C round, highlighting the increasing funding activity in the antibody drug discovery service and platform domain.
In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary after acquiring Abveris, an antibody discovery CRO, in 2022.
Key Topics Covered:
1. PREFACE
2. RESEARCH METHODOLOGY
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
4. EXECUTIVE SUMMARY
5. INTRODUCTION
6. ANTIBODY DISCOVERY: PROCESS AND METHODS
7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
8. COMPANY COMPETITIVENESS ANALYSIS
9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
11. TECHNOLOGY COMPETITIVENESS ANALYSIS
12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
13. PARTNERSHIPS AND COLLABORATIONS
14. FUNDING AND INVESTMENT ANALYSIS
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
25. LICENSING DEAL STRUCTURE
26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
29. CONCLUSION
30. EXECUTIVE INSIGHTS
31. APPENDIX 1: TABULATED DATA
32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
Companies Mentioned
2BScientific
AbBioSci
Abcalis
Abcentra (formerly CardioVax)
Abcepta
Abclonal
ABDYS
Abeome
ABGENEX
Abnova
AbSano
Absci
Absolute Antibody
AbTherx
Abzena
AceMab
Aclys Bio
Adimab
AdipoGen Life Sciences
Administration for Strategic Preparedness and Response (ASPR)
AffinityImmuno
AFSBio
Aganitha
Agency for Science, Technology and Research
Akeagen
Alexion
Almirall
AlpalifeBio
Analytics Engine
Angios
Antibodies-online
Antibody Design Labs
Antibody Solutions
Antiverse
APITBIO
Applied Biological Materials
Applied StemCell
aRNAy Sciences
Aronora
Arsanis
Arvinas
Atlantis Bioscience
Bayer
BeiGene
Berkeley Lights
Bhat Bio-tech India
Big Cypress Acquisition
Bill & Melinda Gates Foundation
BioBench Solutions
BioClue (Acquired by ImmunoPrecise Antibodies)
Bio-Connect
BioD
BioDuro-Sundia
Bioinborn Scientific
BioKey (Acquired by ImmunoPrecise Antibodies)
Biologics International
Biomolecular Discovery Services
BioStrand (Acquired by ImmunoPrecise Antibodies)
Biotecnol
BIOTEM
CALIXAR
Cancer Research UK
Cantargia
Capralogics
Carterra
Catalent Biologics
CD ComputaBio
CDI LaboratoriesCDI Laboratories
Celexion
Celltrion
Celros Biotech
Centers for Disease Control and Prevention
Charles River
ChemPartner
Cherry Biolabs
Cilag
Citryll
City of Hope
Click Chemistry Tools
Coronavirus Immunotherapy Consortium
CP Qingdao
Creative Biostructure
CSL Behring
CureVac
Curia
CUSABIO
Cyclogenix
Daiichi Sankyo
Dako
Danaher
DaTaMabs
DBA Italia
Deerfield Discovery and Development
DetaiBio
Diatheva
Digital Proteomics
discoveric bio
DJS Antibodies
E2DG
e-nnovation Life Sciences
ENPICOM
Enthera
Evitria
EVQLV
Exelixis
exonbio
Faculta (Acquired by Prosci)
Fluoroprobes
Forty Seven
Fred Hutchinson Cancer Center
Fusion Antibodies
G.CLIPS BIOTECH
GeneBeyond
Genedata
GENEWIZ (Acquired by Azenta Life Sciences)
GeneX India Bioscience
Gen-Y Biologics
Government of British Columbia
Government of Canada
Green Mountain Antibodies
Grenoble Hospital
Gustave Roussy
Hangzhou Qiantang River Electric
Harbour Antibodies
Holzel Diagnostika Handels
Horizon Discovery
Humanigen
i2 Pharmaceuticals
IAMA France
immunitoAI
Immunochem
ImmunoChina Pharmaceuticals
ImmunoPrecise Antibodies
ImmunoQure
Immusmol
In-Cell-Art
Indivumed
Integral Molecular
IONTAS
IRBM
Isogenica
ITBMed
Jotbody
KAKEN PHARMACEUTICAL
Kanwhish Biotechnology
KGbio
Kymab
Kyoritsuseiyaku
Kyowa Kirin
LabGenius
Labtoo
LakePharma
Leading Biology
Leads Biolabs
LG Chem
LifeTein
Lonza
Lundbeck
MAB Discovery
Mabpharm
MAbSilico
mAbsolve
Masaachusetts General Hospital
Mass Biologics
Beijing Mede Taikang Biotechnology
MedAbome
MedGenome
MedImmune
MEDx
Memorial Sloan Kettering Cancer Center
Merus
Mila
MI-mAbs
Moderna
Molcure
Molecular Devices
Molecular Templates
Mologic
Moradec
Mount Sinai
MSD
National Research Council of Canada's Human Health Therapeutics Research Centre
NaturalAntibody
Nelum
Neurimmune
Nexum
Nidus MB Technologies
Nkarta
Nordic Society of Gynaecological Oncology
Normunity
NYU Langone Health
Olympic Protein Technologies
OncoC4
OncoResponse
Oncothyreon
Onena Medicines
Open Monoclonal Technology
OriMAbs
Orion
OXGENE
Panoply Bio
Pediatric Brain Tumor Consortium
PharmAbcine
PharmAbs
PharmaEssentia Innovation Research Center
Pierre Fabre
Pioneering Medicines
Precision Antibody
Prometheus Authors
Prosci
Protein Alternatives
ProtTech
Pure Biologics
QoolAbs
Rallybio
Rapid Novor
ReCentrics Biotechnology
Revolve Biotechnologies
RxBiologics
SAb Biotherapeutics
Saccharo
Sanders Tri-Institutional Therapeutics Discovery Institute
Sanyou Biopharmaceuticals
Sartorius
Selecxine
Servier
Shanghai Pidu Biotechnology
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS
Shire
Simcere
Single Cell Technology
SOTIO
Specifica
Sphere Fluidics
Straterx
Sunshine Guojian
Surface Oncology
Surrozen
Symphogen
Synthelis
Takeda
Tasgen Biotech (Acquried by I-Mab Biopharma)
Tasly Biopharmaceuticals
TESARO
Tetra Partner Network
Theranyx
TRANSCENTA
Transgene
TRIANNI
Tubulis
U.S. Naval Medical Research Unit No. 3
Universiti Sains Malaysia
University of Texas MD Anderson Cancer Center
U-Protein (Acquired by ImmunoPrecise Antibodies)
ValenzaBio (Acquired by ACELYRIN)
Valneva
VBI Vaccines
VectorB2B
venBio Partners
VERAXA Biotech
ViralClear Pharmaceuticals
Visterra
Voyager Therapeutics
Washington University School of Medicine
Wisconsin Alumni Research Foundation
WuXi STA
X-Chem
Y- Biologics
Yangyang
YenZym Antibodies
Yinuoke
YUMAB
ZoonBio Biotechnology
For more information about this report visit https://www.researchandmarkets.com/r/1uqj4a
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。